Journal of the Pancreas | Citations & Metrics Report

Articles published in Journal of the Pancreas have been cited by esteemed scholars and scientists all around the world. Journal of the Pancreas has got h-index 82, which means every article in Journal of the Pancreas has got 82 average citations.

Following are the list of articles that have cited the articles published in Journal of the Pancreas.

	2024	2023	2022	2021	2020	2019
Total published articles	59	71	63	53	36	35
Conference proceedings	0	0	0	0	0	0
Citations received as per Google Scholar, other indexing platforms and portals	1082	1479	1640	2162	2116	2183

Journal total citations count	42521
Journal impact factor	24.75
Journal 5 years impact factor	38.93
Journal cite score	35.06
Journal h-index	82

Important citations

Determination of Causal Relationship Between Bilirubin and Other Liver Biomarker in Case of Hepatitis C. Biomed Stat Inform 2021; 6:23-31.

Das RN. Determinants of total bilirubin for liver patients. J Liver Res Disord Ther 2018; 4:130-134.

Mohamed AA, Hemeda AA, Aziz RK, Abdel-Hakeem MS, Ali-Tammam M. Body mass index (BMI) and alpha-fetoprotein (AFP) level correlate with the severity of HCV-induced fibrosis in a cohort of Egyptian patients with chronic HCV. Future J Pharm Sci 2020; 6:71.

Abbas MT. The Prophylactic and Protective Effects of Terfezia Claveryi Extracts on Ibuprofen Induced Oxidative Stress in Pregnant Rats. Gazi Med J 2019; 30.

Saffo S, Peng C, Salem R, Taddei T, Nagar A. Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. Dig Dis Sci 2021; 21:06967-06967. [PMID: 33811566].

Panteleev VI, Kaldarov AR, Gorin DS, Kriger AG. Combination of intraductal papillary mucinous neoplasm with other cystic pancreatic tumors. Khirurgiia (Mosk) 2021; 2:80-83. [PMID: 33570359].

Kriger AG, Gorin DS, Berelavichus SV, Panteleev VI, Kaldarov AR. Successful Surgical Treatment of a Patient with Synchronic Intraductal Papillary Mucinous Carcinoma and Solid Pseudopapillary Neoplasm of the Pancreas. Gastrointest Tumors 2020; 7:151-155.

Zhukova LG, Grechukhina KS, Smolin SA, Bammatov BI. The role of systemic therapy in localized pancreatic cancer (literature review). Ann Hepatol 2019; 24:365-372

Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. J Surg Oncol 2021.

Nassabein R, Tabchi S, Richard C, Routy B, Ayoub J, Aubin F, et al. Neoadjuvant Therapy (NAT) in Pancreatic Adenocarcinoma (PAC): A Single Center Experience. J Cancer Sci Clin Ther 2019; 3:266-277.

Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, et al. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers (Basel) 2021; 13:4326. [PMID: 34503138].

Tang R, Meng Q, Wang W, Liang C, Hua J, Xu J, et al. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. Gland Surg 2021; 10:1564-1575. [PMID: 34164301].

Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J, et al. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. Surg Oncol 2020; 35:285-297. [PMID: 32949968].

Tanaka H, Imai H, Higashi T, Murase K, Matsuhashi N, Yoshida K. Splenic artery transposition for hepatic arterial reconstruction in conversion surgery of an initially unresectable, locally advanced pancreatic cancer after gemcitabine/nab-paclitaxel: A case report. Int J Surg Case Rep 2021; 78:192-196. [PMID: 33360334].

Lowder CY, Dhir T, Goetz AB, Thomsett HL, Bender J, Tatarian T, et al. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surg Oncol 2020; 33:118-125. [PMID: 32561076].

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Front Oncol 2020; 10:1461. [PMID: 33042792].

Napoli N, Kauffmann E, Cacace C, Menonna F, Caramella D, Cappelli C, et al. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Updates Surg 2021; 73:233-249. [PMID: 32978753].

Capello M, Fahrmann JF, Perez MVR, Vykoukal JV, Irajizad E, Tripathi SC, et al. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol 2020 :4, 426-436.

Choi YJ, Byun Y, Kang JS, Kim HS, Han Y, Kim H, et al. Comparison of clinical outcomes of borderline resectable pancreatic cancer according to the neoadjuvant chemo-regimens: Gemcitabine versus FOLFIRINOX. Gut Liver 2021; 15:466-475. [PMID: 32839360].

Kelly KN, Macedo FI, Merchant NB. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? Adv Surg 2020; 54:49-68. [PMID: 32713439].